Drug Trial Radar · NCT06494501
The Prevent Coronary Artery Disease Trial
Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,600
Planned (sponsor's estimate)
Start
Sep 12, 2024
Primary completion
Jun 30, 2032
Study completion Jun 30, 2032
Sponsor
- Lead sponsor
- Icahn School of Medicine at Mount SinaiAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Despite increasing evidence that exposure to cardiovascular risk factors (CVRF) at an early age increases the prevalence of subclinical atherosclerosis and is associated with a greater risk of cardiovascular events later in life, there is a lack of randomized trial evidence to support primary prevention strategies in adults aged 30-50 years. The researchers have designed a randomized controlled trial to evaluate whether strict control of CVRF in young adults without known cardiovascular disease, will reduce the progression of total atherosclerosis burden, a surrogate endpoint for symptomatic cardiovascular disease, compared with usual care. The researchers propose a randomized controlled trial enrolling 1,600 healthy young adults who meet the inclusion criteria and who do not meet any exclusion criteria. Eligible study participants will be randomized, in a 1:1 ratio, to either the intervention group (active treatment strategy) or to the control group (guideline-directed medical therapy). Randomization will be stratified by the presence or absence of atherosclerotic plaque in vascular ultrasound.
Conditions
- Atherosclerotic Cardiovascular Disease
Interventions
InclisiranDrug
Subjects will be administered a single subcutaneous injection of 284 mg inclisiran for injection at predefined time points.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in atherosclerotic plaque burden from baselineTime frame: Baseline, 2.5 years and 5 years after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mount Sinai Fuster Heart Hospital
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.